AstraZeneca Posts Second-Quarter Profit Rise Driven by Cancer Drugs
Strong cancer drug sales have lifted Anglo-Swedish pharmaceutical giant AstraZeneca’s second-quarter earnings above expectations, allowing the firm to maintain its outlook.
AI disclosure: Summarised from a single named source by an AI model with editorial rules; links to the original report.
According to Euronews, Anglo-Swedish pharmaceutical giant AstraZeneca has reported a 2 percent rise in quarterly net profit, driven largely by strong sales of its cancer drugs. The robust financial performance pushed the company's second-quarter earnings above market expectations.
The positive results have also enabled the pharmaceutical company to confidently maintain its existing outlook for 2026.
Source: Euronews. Read the original report ↗
Source ledger
-
This brief is based on reporting by Euronews.supports: Euronews